Telmisartan

Telmisartan
Clinical data
Pronunciation	/tɛlmɪˈsɑːrtən/
Trade names	Micardis, others
AHFS/Drugs.com	Monograph
MedlinePlus	a601249
License data	US DailyMed: Telmisartan;
Pregnancy; category	AU: D; Not recommended;
Routes of; administration	By mouth
Drug class	Angiotensin II receptor antagonist
ATC code	C09CA07 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	42–100%
Protein binding	>99.5%
Metabolism	Minimal liver (glucuronidation)
Elimination half-life	24 hours
Excretion	Feces 97%
Identifiers
	IUPAC name 2-(4-{[4-Methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}phenyl)benzoic acid;
CAS Number	144701-48-4 ;
PubChem CID	65999;
IUPHAR/BPS	592;
DrugBank	DB00966 ;
ChemSpider	59391 ;
UNII	U5SYW473RQ;
KEGG	D00627 ;
ChEBI	CHEBI:9434 ;
ChEMBL	ChEMBL1017 ;
CompTox Dashboard (EPA)	DTXSID8023636 ;
ECHA InfoCard	100.149.347
Chemical and physical data
Formula	C33H30N4O2
Molar mass	514.629 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)c1ccccc1c2ccc(cc2)Cn3c4cc(cc(c4nc3CCC)C)c5nc6ccccc6n5C;
	InChI InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39) ; Key:RMMXLENWKUUMAY-UHFFFAOYSA-N ;
	(verify)

Telmisartan, sold under the brand name Micardis among others, is a medication used to treat high blood pressure and heart failure. It is a reasonable initial treatment for high blood pressure. It is taken by mouth.

Common side effects include upper respiratory tract infections, diarrhea, and back pain. Serious side effects may include kidney problems, low blood pressure, and angioedema. Use in pregnancy may harm the baby and use when breastfeeding is not recommended. It is an angiotensin II receptor blocker and works by blocking the effects of angiotensin II.

Telmisartan was patented in 1991 and came into medical use in 1999. It is available as a generic medication. In 2022, it was the 228th most commonly prescribed medication in the United States, with more than 1 million prescriptions. It is available in combination with hydrochlorothiazide as telmisartan/hydrochlorothiazide; with cilnidipine as telmisartan/cilnidipine; and with amlodipine as telmisartan/amlodipine.